Abstract: Transfer devices with vial adapter and/or an infusion set for reducing overdosing/underdosing of an infusion bag are provided. The transfer device provides user- controlled fluid transferring between an infusion liquid container and a drug-containing container. In one aspect, the transfer device provides user-controlled venting that can be used during liquid transfer between the infusion liquid container and a drug-containing container.

Abstract: A vial access device comprising an first housing comprising a vent body having a cover configured for reversibly hermetically sealing the vent body; a first spike having a proximal end and a distal end, the proximal end projecting from the first housing, the first spike having a fluid lumen and a vent lumen, each arranged parallel to the first longitudinal axis, the vent lumen in fluidic communication with the vent body; a shroud projecting the first housing and at least partially surrounding a portion of the first spike; the shroud configured to receive a vial or container; a connector member projecting from the first housing, the connector in fluid communication with the fluid lumen of the first spike. Methods of transferring solutions from medicament vials are also provided.

Abstract: Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.

Abstract: Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012–1×1013 vector genomes/ml.

Abstract: Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012-1×1013 vector genomes/ml.

Abstract: Serotype 1 recombinant adeno-associated virus (rAAV) vectors were used to deliver functional acid alpha-glucosidase genes in vitro and in vivo to muscle cells deficient in acid alpha-glucosidase. The vector-treated cells overexpressed acid alpha-glucosidase. Vector-treated animals displayed restored enzymatic activity and muscle function. Serotype 1 rAAV vectors induced significantly greater acid alpha-glucosidase expression compared to serotype 2 rAAV vectors.